Tag - daiichi-sankyo

 
 

DAIICHI SANKYO

JAPAN / Science & Health
Aug 31, 2020
Daiichi Sankyo's COVID-19 vaccine candidate selected by Japanese drug discovery body
Daiichi Sankyo Co. said on Monday that its mRNA-based COVID-19 vaccine candidate was selected for inclusion in a drug discovery program by the Japan Agency for Medical Research and Development.
Japan Times
BUSINESS / Companies
Jul 28, 2020
Astra to pay Daiichi up to $6 billion for new cancer drug
AstraZeneca is forging ahead to become a global oncology powerhouse, even as it works on a vaccine for the coronavirus pandemic.
Japan Times
JAPAN / Science & Health
Jun 16, 2019
Drug devised to replace chemotherapy may reshape cancer care
A class of drugs is emerging that can attack cancer cells in the body without damaging surrounding healthy ones. They have the potential to replace chemotherapy and its disruptive side effects, reshaping the future of cancer care.
Japan Times
BUSINESS / Companies
Mar 29, 2019
AstraZeneca bets $6.9 billion that Daiichi Sankyo therapy will transform cancer treatment
Britain's AstraZeneca's biggest deal in recent memory give it access to the Japanese drugmaker's promising but difficult to pronounce cancer treatment: trastuzumab deruxtecan.
Japan Times
BUSINESS / Companies
Sep 29, 2017
Opioids demand rises in Japan as seniors use drugs to ease pain and improve quality of life
Selling painkillers in Japan used to be like pulling teeth. That was until baby boomers discovered how analgesics could take the sting from arthritis, diabetic nerve damage and the ravages of cancer.
Japan Times
BUSINESS / Companies
Aug 2, 2017
Daiichi Sankyo settles U.S. lawsuits over intestinal damage from blood-pressure drugs, paying $300 million
Daiichi Sankyo Inc. has settled thousands of lawsuits alleging its blood-pressure drugs caused intestinal damage, bringing to $339 million the amount the drugmaker has paid over the medicines.
Japan Times
BUSINESS / Companies
Feb 9, 2015
Growth concerns loom for Daiichi Sankyo on drug warning
Daiichi Sankyo Co. risks losing a slice of revenue to generic-medicine competition next year. Now, the drugmaker's plans to fill the gap have hit a roadblock and investors worry that growth may flounder.
Japan Times
BUSINESS / Companies
Sep 29, 2014
Daiichi Sankyo to buy Ambit to strengthen cancer product line
Daiichi Sankyo Co. has agreed to buy U.S.-based Ambit Biosciences Corp. for as much as $410 million to bolster its pipeline of cancer treatments.

Longform

Professional cleaner Hirofumi Sakurai takes a moment to appreciate some photographs in a Gotanda apartment whose occupant died alone.
The last cleanup: Life and death in a lonely Japan